Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 华兰疫苗是一家专业从事人用疫苗研发、生产、销售的高新技术企业。截至本招股意向书签署日，华兰疫苗已上市的产品主要包括流感病毒裂解疫苗、四价流感病毒裂解疫苗、甲型H1N1流感病毒裂解疫苗、重组乙型肝炎疫苗（汉逊酵母）以及ACYW135群脑膜炎球菌多糖疫苗、A群C群脑膜炎球菌多糖疫苗等；已获批准临床试验或已通过临床待注册上市的产品主要包括人用狂犬病疫苗（Vero细胞）、吸附破伤风疫苗、冻干A群C群脑膜炎球菌结合疫苗、H7N9流感病毒裂解疫苗、H7N9流感全病毒灭活疫苗、吸附无细胞百（三组分）白破联合疫苗、重组冠状病毒肺炎疫苗（重组人5型腺病毒载体）等；处于临床前研究阶段产品包括新型冠状病毒灭活疫苗（vero细胞）、冻干鼻喷重组新型冠状病毒减毒活疫苗，产品布局覆盖流行性感冒、流行性脑膜炎、乙型肝炎、狂犬病、百日咳、白喉及破伤风等多种疾病。 公司主要产品为人用疫苗，已上市的产品可分为病毒性疫苗、细菌性疫苗和基因重组类疫苗。
Main Business 人用疫苗研发、生产、销售。
Legal Representative 安康
Top Executives
董事长：安康
董事：安文珏,安文琪,马小伟,潘若文,范蓓
独立董事：李德新,杨东升,章金刚
Top 5 Shareholder
Shareholder name Nature Holding Date
华兰生物工程股份有限公司限售股67.38%30/09/2024
CYBERCREATORLIMITED科康有限公司限售股8.98%30/09/2024
新乡晨壹启明管理咨询合伙企业（有限合伙）流通A股4.99%30/09/2024
河南骅盈企业管理咨询合伙企业（有限合伙）流通A股3.99%30/09/2024
华兰生物疫苗股份有限公司回购专用证券账户流通A股1.00%30/09/2024
Company Secretary 吕成玉
Solicitors 安徽承义律师事务所
Auditors 大华会计师事务所（特殊普通合伙）
Tel No 0373-3559909
Fax No 0373-3559909
Website www.hualanbacterin.com
Email hlym@hualan.com；lcy1151@hualan.com；ll5895@hualan.com
Company Address
Register: 河南省新乡市华兰大道甲1号附1号
Office: 河南省新乡市华兰大道甲1号附1号
Listing Date 18/02/2022
Shares Capital
Shares Capital: 601,027,500
Total A Share: 601,027,500
Listed A Share: 141,648,488
Non-tradable A Share: 459,379,012
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.432
DPS(RMB)* ¥ 0.600
NBV Per Share(RMB)* ¥ 10.438
Market Capitalization(RMB) 2.613B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.